| abstract |
Compounds of formula I are novel effective PDE4 inhibitors: Formula I Where R 1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or fully or mainly fluorine-substituted 1-4C-alkoxy ego, R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or fully or mainly fluorine-substituted 1-4C-alkoxy Or R1 and R2 together are a 1-2C-alkylenedioxy group, R 3 is hydrogen or 1-4C-alkyl, R31 is hydrogen or 1-4C-alkyl, In a first embodiment (embodiment a) according to the invention, R4 is -O-R41, Wherein R 41 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-7C-alkylcarbonyl, or fully or mainly fluorine-substituted 1-4C-alkyl, R 5 is hydrogen or 1-4C-alkyl, or In a second embodiment according to the invention (embodiment b), R 4 is hydrogen or 1-4C-alkyl, R5 is -O-R51, Wherein R 51 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-7C-alkylcarbonyl, or fully or mainly fluorine-substituted 1-4C-alkyl, Har is a 5- to 10-membered monocyclic or fused bixy optionally substituted with R 6 and / or R 7 and / or R 8 and comprising 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur Click unsaturated or partially saturated heteroaryl radicals. |